Loading clinical trials...
Loading clinical trials...
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic e...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Telios Pharma, Inc.
NCT05839938 · Allergic Conjunctivitis
NCT05186025 · Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis, and more
NCT01471184 · Allergic Rhinitis, Allergic Conjunctivitis
NCT06602726 · Allergic Conjunctivitis
NCT05191186 · Allergic Rhinitis Due to Grass Pollen, Allergic Conjunctivitis of Both Eyes, and more
Telios Investigative Site
Memphis, Tennessee
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions